First Time Loading...

Mirati Therapeutics Inc
NASDAQ:MRTX

Watchlist Manager
Mirati Therapeutics Inc Logo
Mirati Therapeutics Inc
NASDAQ:MRTX
Watchlist
Price: 58.7 USD Market Closed
Updated: Apr 29, 2024

Mirati Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mirati Therapeutics Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Mirati Therapeutics Inc
NASDAQ:MRTX
Revenue
$38.2m
CAGR 3-Years
46%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.1B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

Mirati Therapeutics Inc
Revenue Breakdown

Breakdown by Geography
Mirati Therapeutics Inc

Not Available

Breakdown by Segments
Mirati Therapeutics Inc

Total Revenue: 12.4m USD
100%
License And Collaboration Revenues: 11.7m USD
94.2%
Product Revenue, Net: 713k USD
5.7%

See Also

What is Mirati Therapeutics Inc's Revenue?
Revenue
38.2m USD

Based on the financial report for Sep 30, 2023, Mirati Therapeutics Inc's Revenue amounts to 38.2m USD.

What is Mirati Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
32%

Over the last year, the Revenue growth was 224%. The average annual Revenue growth rates for Mirati Therapeutics Inc have been 46% over the past three years , 32% over the past five years .